Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01360593 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by David A. Clump, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01360593 is a Phase 2 study that has completed, run by David A. Clump, MD, PhD. The registered enrollment target is 35 participants.
The verdict
NCT01360593, a Phase 2 study, has completed, sponsored by David A. Clump, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The current study seeks to further investigate the impact of up-front systemic therapy in combination with fractionated SBRT for potentially resectable, locally-advanced pancreatic adenocarcinoma.
Interventions
- DRUG Capecitabine
- DRUG Gemcitabine
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-07-25 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01360593
The ClinicalTrials.gov registry entry for NCT01360593 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David A. Clump, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT01360593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01360593 about?
NCT01360593 is a clinical study titled "Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma". The current study seeks to further investigate the impact of up-front systemic therapy in combination with fractionated SBRT for potentially resectable, locally-advanced pancreatic adenocarcinoma.
What is the current status of trial NCT01360593?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2011-07-25. Estimated completion is 2018-10.
What interventions are being tested in trial NCT01360593?
The interventions under investigation include: Capecitabine (DRUG), Gemcitabine (DRUG), Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01360593?
This trial is sponsored by David A. Clump, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.